8-K filed April 20, 2026, 7:59 PM ET ticker TRAX CIK 0002091349

other material confidence medium sentiment neutral materiality 0.80

First Tracks Biotherapeutics completes spin-off from AnaptysBio and raises ~$80M in private placement

First Tracks Biotherapeutics, Inc.

Spin-off effective April 20, 2026; AnaptysBio holders received one First Tracks share per AnaptysBio share held on April 6 record date.
Private placement of ~10.5M shares at $13.81: company issued 5.79M shares (~$80M proceeds) and selling stockholder sold 4.71M shares.
Entered Separation and Distribution and Transition Services Agreements with AnaptysBio to govern asset/liability split and post-spin operations.
First Tracks received $100M cash and rights to up to $35M in milestone payments from Vanda Pharmaceuticals collaboration.

item 1.01 item 2.01 item 3.02 item 3.03 item 5.03 item 5.01 item 5.02 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-164328
form_type: 8-K
ticker: TRAX
cik: 0002091349
company_name: First Tracks Biotherapeutics, Inc.
filed_at: 2026-04-20T23:59:59+00:00
discovered_at: 2026-05-14T18:02:33.488298+00:00
generated_at: 2026-05-15T05:23:55.311056+00:00
sec_items: ["1.01", "2.01", "3.02", "3.03", "5.03", "5.01", "5.02", "8.01", "9.01"]
event_type: other_material
sentiment: neutral
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: medium
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-164328
json_url: https://secwatch.observer/filing/0001193125-26-164328.json
markdown_url: https://secwatch.observer/filing/0001193125-26-164328.md
text_url: https://secwatch.observer/filing/0001193125-26-164328.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/2091349/000119312526164328/0001193125-26-164328-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/2091349/000119312526164328/d78703d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source-grounded claims

0a45008cb1e1fe1b7379f1bd6d2da84ffa83caca

First Tracks Biotherapeutics, Inc.: Amended and Restated Certificate of Incorporation became effective in connection with the Spin-Off.

We filed an Amended and Restated Certificate of Incorporation (the “Charter”) with the Secretary of State of the State of Delaware, which became effective in connection with the Spin-Off.

SEC 8-K Item 5.03/5.05/5.06 confidence 0.9 SEC evidence

a88750d1fb66a91688e3a72d2d96f4c2f9e9c9e2

First Tracks Biotherapeutics, Inc.: Bylaws became effective in connection with the Spin-Off.

Our Bylaws (the “Bylaws”) also became effective in connection with the Spin-Off.

SEC 8-K Item 5.03/5.05/5.06 confidence 0.9 SEC evidence

3a58de5f73c71c9b0f1d5a66a86ee0ead88512a3

First Tracks Biotherapeutics, Inc. completed a disposition involving AnaptysBio, Inc. (closed 2026-04-20).

On the Distribution Date, AnaptysBio completed the Spin-Off.

SEC 8-K Item 2.01/5.01 confidence 0.95 SEC evidence

1b2ad13ee33d11bd021bf1c882ba15bd88328ac7

First Tracks Biotherapeutics, Inc. entered into Transition Services Agreement with AnaptysBio.

the Company entered into a Separation and Distribution Agreement and a Transition Services Agreement (collectively, the "Spin Agreements") with AnaptysBio

SEC 8-K Item 1.01/1.02 confidence 0.9 SEC evidence

631470f7340f756208beb551f2662015c19a999e

First Tracks Biotherapeutics, Inc. entered into Separation and Distribution Agreement with AnaptysBio.

the Company entered into a Separation and Distribution Agreement and a Transition Services Agreement (collectively, the "Spin Agreements") with AnaptysBio

SEC 8-K Item 1.01/1.02 confidence 0.9 SEC evidence

Comparable filings

DGAC

Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE

DISCIPLINED GROWTH ACQUISITION Corp June 1, 2026, 4:15 PM ET other_material Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01

same fact type: governance_change, material_agreement same SEC item: 1.01, 3.02, 5.02, 5.03, 8.01, 9.01 same event type: other_material similar materiality

This filing

We filed an Amended and Restated Certificate of Incorporation (the “Charter”) with the Secretary of State of the State of Delaware, which became effective in connection with the Spin-Off.

Comparable filing

On May 26, 2026, in connection with the IPO, the Company filed its amended and restated memorandum and articles of association (the “Amended and Restated Memorandum and Articles of Association”) with the Cayman Islands Registrar of Companies, which was effective on May 26, 2026.

Filing page SEC filing

SAGU

Shreya Acquisition Group closes $110M IPO, 11M units at $10 each on NYSE

Shreya Acquisition Group May 11, 2026, 7:59 PM ET other_material Items 1.01, 3.02, 5.02, 5.03, 8.01, 9.01

same fact type: governance_change, material_agreement same SEC item: 1.01, 3.02, 5.02, 5.03, 8.01, 9.01 same event type: other_material similar materiality

This filing

We filed an Amended and Restated Certificate of Incorporation (the “Charter”) with the Secretary of State of the State of Delaware, which became effective in connection with the Spin-Off.

Comparable filing

On May 6, 2026, and in connection with the IPO, the Company adopted its Amended and Restated Memorandum and Articles of Association.

Filing page SEC filing

SUJA

Suja Life completes IPO of 8.9M shares at $21/share; closes May 8, 2026

SUJA LIFE, INC. May 8, 2026, 7:59 PM ET other_material Items 1.01, 3.02, 3.03, 5.03, 5.02, 9.01

same fact type: governance_change, material_agreement same SEC item: 1.01, 3.02, 3.03, 5.02, 5.03, 9.01 same event type: other_material similar materiality

This filing

We filed an Amended and Restated Certificate of Incorporation (the “Charter”) with the Secretary of State of the State of Delaware, which became effective in connection with the Spin-Off.

Comparable filing

On May 7, 2026, the Company filed an amended and restated certificate of incorporation (the “Certificate of Incorporation”) with the Secretary of State of the State of Delaware

Filing page SEC filing

CLRB

Cellectar raises ~$35M via stock/warrant offering; reports positive 12-mo Phase 2b WM data

Cellectar Biosciences, Inc. May 8, 2026, 7:59 PM ET other_material Items 1.01, 3.02, 8.01, 9.01

same fact type: material_agreement same SEC item: 1.01, 3.02, 8.01, 9.01 same event type: other_material similar materiality

This filing

the Company entered into a Separation and Distribution Agreement and a Transition Services Agreement (collectively, the "Spin Agreements") with AnaptysBio

Comparable filing

pursuant to an additional securities purchase agreement with certain members of the executive management team of the Company (the “Management Purchase Agreement”

Filing page SEC filing

ADT

Apollo sells all 102M ADT shares; ADT repurchases 29.1M shares in $1.5B plan

ADT Inc. May 8, 2026, 7:59 PM ET other_material Items 5.02, 5.03, 8.01, 9.01

same fact type: governance_change same SEC item: 5.02, 5.03, 8.01, 9.01 same event type: other_material similar materiality

This filing

We filed an Amended and Restated Certificate of Incorporation (the “Charter”) with the Secretary of State of the State of Delaware, which became effective in connection with the Spin-Off.

Comparable filing

On May 8, 2026, the Board approved an amendment and restatement of the Company’s Amended and Restated Bylaws, dated as of September 15, 2023 (as amended, the “ Bylaws ”), to remove references related to Apollo and the Amended and Restated Stockholders Agreement, dated December 14, 2018, between the Company, Prime Security Services TopCo Parent, L.P., and the Co-Investors.

Filing page SEC filing

KRMN

Selling stockholders price upsized secondary offering of 14M shares at $61/share for ~$854M gross proceeds

Karman Holdings Inc. June 1, 2026, 5:28 PM ET other_material Items 1.01, 7.01, 8.01, 9.01

same fact type: material_agreement same SEC item: 1.01, 8.01, 9.01 same event type: other_material similar materiality

This filing

the Company entered into a Separation and Distribution Agreement and a Transition Services Agreement (collectively, the "Spin Agreements") with AnaptysBio

Comparable filing

On May 28, 2026, Karman Holdings Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with the persons named in Schedule II thereto (the “Selling Stockholders”) and Citigroup Global Markets Inc. and Evercore Group L.L.C., as the underwriters (the “Underwriters”), pursuant to which the Selling Stockholders agreed to sell 14,000,000 shares of common stock, par value $0.001 per share, of the Company (the “Common Stock”) at a public offering price of $61.00 per share (the “Offering Price”), less underwriting discounts and commissions (the “Offering”).

Filing page SEC filing

XRN

Chiron Real Estate enters $100M preferred equity deal with Maewyn XRN LP

Chiron Real Estate Inc. May 8, 2026, 7:59 PM ET other_material Items 1.01, 3.02, 9.01

same fact type: material_agreement same SEC item: 1.01, 3.02, 9.01 same event type: other_material similar materiality

This filing

the Company entered into a Separation and Distribution Agreement and a Transition Services Agreement (collectively, the "Spin Agreements") with AnaptysBio

Comparable filing

In connection with the Private Placement, on May 6, 2026, the Company and the Purchasers entered an Investor Rights Agreement.

Filing page SEC filing

NKTR

Nektar enters $150M ATM equity agreement; appoints Linda Rubinstein as interim CFO

NEKTAR THERAPEUTICS May 8, 2026, 7:59 PM ET other_material Items 1.01, 5.02, 9.01

same fact type: material_agreement same SEC item: 1.01, 5.02, 9.01 same event type: other_material similar materiality

This filing

the Company entered into a Separation and Distribution Agreement and a Transition Services Agreement (collectively, the "Spin Agreements") with AnaptysBio

Comparable filing

On May 8, 2026, Nektar Therapeutics (the “Company”) entered into an Equity Distribution Agreement (the “Agreement”) with Guggenheim Securities, LLC (“Guggenheim Securities”) and H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which the Company may offer and sell, from time to time in its sole discretion, shares of its common stock, par value $0.0001 per share (the “Common Stock”) having an aggregate offering price of up to $150,000,000 (the “Shares”), through Guggenheim Securities and Wainwright as its sales agents.

Filing page SEC filing

Source: SEC EDGAR

accession 0001193125-26-164328

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.